Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model

被引:30
作者
Dursun, Ayhan [1 ]
Arici, Mustafa Kemal [1 ]
Dursun, Feyza [1 ]
Ozec, Ayse Vural [1 ]
Toker, Mustafa Ilker [1 ]
Erdogan, Haydar [1 ]
Topalkara, Aysen [1 ]
机构
[1] Cumhuriyet Univ, Sch Med, Dept Ophthalmol, Sivas, Turkey
关键词
corneal neovascularisation; bevacizumab; ranibizumab; ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; IN-VITRO; NEOVASCULARIZATION; AVASTIN; THERAPY; SAFETY; CELLS;
D O I
10.3980/j.issn.2222-3959.2012.04.08
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
AIM: To investigate the effects of bevacizumab and ranibizumab on corneal neovascularization in an alkali bum-induced model of corneal angiogenesis. METHODS: Fifteen Wistar-Albino rats were divided randomly into 3 groups after chemical cauterization of the cornea. The first group received a single dose of 0.1mL saline solution as a control group whereas second and third groups received a single dose of 2.5mg bevacizumab or 1mg ranibizumab by subconjunctival injection, respectively. After three weeks, the rat corneas were evaluated by biomicroscopy and corneal photographs were taken. The percentage of neovascularization area, length of the longest new vessel, corneal oedema and corneal opacity scores were assessed. RESULTS: The analysis of digital photographs showed that the percentage of neovascularization area to the total corneal area, the length of the longest new vessel, corneal oedema and opacity scores were significantly lower in both study groups compared to the control group (P<0.05). Additionally, the percentage of corneal neovascularization area, the length of the longest new vessel and corneal opacity score were less with bevacizumab than ranibizumab. CONCLUSION: Subconjunctival bevacizumab and ranibizumab treatments may be effective methods in reducing corneal neovascularization Furthermore, bevacizumab is more effective than ranibizumab in the inhibition of corneal neovascularization.
引用
收藏
页码:448 / 451
页数:4
相关论文
共 23 条
[1]   Effect of bevacizumab on corneal neovascularization in experimental rabbit model [J].
Ahmed, Abdulgani ;
Berati, Hasanreisoglu ;
Nalan, Akyurek ;
Aylin, Sepici .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 37 (07) :730-736
[2]   Bevacizumab (Avastin) eye drops inhibit corneal neovascularization [J].
Bock, Felix ;
Koenig, Yanyan ;
Kruse, Friedrich ;
Baier, Martin ;
Cursiefen, Claus .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2008, 246 (02) :281-284
[3]   Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis [J].
Bock, Felix ;
Onderka, Jasmine ;
Dietrich, Tina ;
Bachmann, Bjorn ;
Kruse, Friedrich E. ;
Paschke, Matthias ;
Zahn, Grit ;
Cursiefen, Claus .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2007, 48 (06) :2545-2552
[4]   Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study [J].
Brown, David M. ;
Michels, Mark ;
Kaiser, Peter K. ;
Heier, Jeffrey S. ;
Sy, Judy P. ;
Ianchulev, Tsontcho .
OPHTHALMOLOGY, 2009, 116 (01) :57-65
[5]   Corneal neovascularization [J].
Chang, Jin-Hong ;
Gabison, Eric E. ;
Kato, Takuji ;
Azar, Dimitri T. .
CURRENT OPINION IN OPHTHALMOLOGY, 2001, 12 (04) :242-249
[6]  
DANA MR, 1995, CORNEA, V14, P604
[7]   Application of Topical/Subconjunctival Bevacizumab and Topical Fluorometholone Acetate in Alkali Burn-induced Model of Corneal Angiogenesis [J].
Dursun, Ayhan ;
Arici, Mustafa Kemal ;
Ozec, Ayse Vural ;
Dursun, Feyza ;
Toker, Mustafa Ilker ;
Topalkara, Aysen .
TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2010, 40 (06) :318-322
[8]   Ranibizumab in neovascular age-related macular degeneration [J].
Eng, Kenneth T. ;
Kertes, Peter J. .
CLINICAL INTERVENTIONS IN AGING, 2006, 1 (04) :451-466
[9]   Safety of intravitreal injection of bevacizumab in rabbit eyes [J].
Feiner, Leonard ;
Barr, Emily E. ;
Shui, Ying-Bo ;
Holekamp, Nancy M. ;
Brantley, Milam A. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (08) :882-888
[10]   Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy [J].
Ferrara, N ;
Hillan, KJ ;
Novotny, W .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) :328-335